Related Experiment Videos
Photodynamic therapy for corneal neovascularization
G B Primbs1, R Casey, K Wamser
1Jules Stein Eye Institute, University of California at Los Angeles, USA.
Ophthalmic Surgery and Lasers
|October 30, 1998
Summary
Photodynamic therapy using tin ethyl etiopurpurin (SnET2) effectively treated rat corneal neovascularization. This method demonstrated prolonged neovessel closure with minimal side effects in a preclinical model.
Area of Science:
- Ophthalmology
- Photomedicine
- Vascular Biology
Background:
- Corneal neovascularization poses a significant risk to vision.
- Current treatments for corneal neovascularization have limitations.
Purpose of the Study:
- To evaluate photodynamic therapy (PDT) with tin ethyl etiopurpurin (SnET2) for treating corneal neovascularization in a rat model.
- To determine the safety and efficacy of SnET2-mediated PDT.
Main Methods:
- Rats received intravenous SnET2 followed by focal 664 nm laser light application to corneal neovascularization.
- Escalating light doses were tested, with controls receiving light or drug only.
- Clinical, angiographic, and histopathologic assessments were conducted up to 28 days post-treatment.
Main Results:
- A dose-dependent response was observed between SnET2 and light, leading to neovessel closure.
- The highest light dose (25 J/cm2) resulted in complete occlusion in all treated eyes by day 28.
- Control groups exhibited progressive corneal neovascularization throughout the study period.
Conclusions:
- Photodynamic therapy with SnET2 is a safe and effective treatment for corneal neovascularization in a rat model.
- Prolonged occlusion (> 28 days) of neovessels was achieved with minimal adverse effects.
- The study supports PDT as a promising therapeutic strategy for ocular neovascular diseases.